Germany · Delayed Price · Currency is EUR Cardiff Oncology Company Description
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers.
Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC.
The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012.
Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 33 |
| CEO | Mark Erlander |
Contact Details
Address: 11055 Flintkote Avenue San Diego, Delaware 92121 United States | |
| Phone | 858 952 7570 |
| Website | cardiffoncology.com |
Stock Details
| Ticker Symbol | XE7C |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark Erlander | Chief Executive Officer |
| James Levine | Chief Financial Officer |